Used primarily in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon (CRBN)-based E3 ligase modulators. Its structural features enable selective binding to CRBN, facilitating the ubiquitination and subsequent degradation of disease-related proteins. This makes it valuable in developing treatments for cancers, especially hematological malignancies like multiple myeloma and myelodysplastic syndromes. It is also explored in the design of PROTACs (proteolysis-targeting chimeras) for degrading otherwise undruggable targets. Due to its bromo and methoxy functional groups, it serves as a versatile building block for further chemical modifications in drug discovery programs.